Skip to main content
SpringerLink
Log in

Dyslipidemias

  • Chapter
Inborn Metabolic Diseases

  • 2975 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Goldstein JL, Brown MS (2001) Molecular medicine. The cholesterol quartet. Science 292:1310–1312

    Article  PubMed  CAS  Google Scholar 

  2. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125–1131

    Article  PubMed  CAS  Google Scholar 

  3. Rader D (2002) High-density lipoproteins and atherosclerosis. Am J Cardiol 90(Suppl):62i–70i

    Article  PubMed  CAS  Google Scholar 

  4. Heinecke JW, Lusis AJ (1998) Paraoxonase-gene polymorphisms associated with coronary heart disease: Support for the oxidative damage hypothesis? Am J Hum Genet 62:36–44

    Article  Google Scholar 

  5. Yesilaltay A, Kocher O, Rigotta A, Krieger M (2005) Regulation of SR-BI-mediated high-density lipoprotein metabolism by the tissuespecific adaptor protein PDZK1. Curr Opin Lipidol 16:147–152

    Article  PubMed  CAS  Google Scholar 

  6. Rubins HB, Robins SJ, Collins D et al (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410–418

    Article  PubMed  CAS  Google Scholar 

  7. Bezafibrate Infarction Prevention Study Group (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21–27

    Google Scholar 

  8. Rouis M, Dugi KA, Previato L et al (1997) Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arterioscler Thromb Vasc Biol 17:1400–1406

    PubMed  CAS  Google Scholar 

  9. Kwiterovich Jr PO (2002) Clinical relevance of the biochemical, metabolic and genetic factors that influence low density lipoprotein heterogeneity. Am J Cardiol 90:30i–48i (Suppl 8A)

    Article  PubMed  CAS  Google Scholar 

  10. Millar JS, Packard CJ (1998) Heterogeneity of apolipoprotein B-100-containing lipoproteins: What we have learnt from kinetic studies. Curr Opin Lipidol 9:197–202

    Article  PubMed  CAS  Google Scholar 

  11. Maslowska M, Wang HW, Cianflone K (2005) Novel roles for acylation stimulatory protein/C3a desArg: a review of recent in vitro and in vivo evidence. Vitam Horm 70:309–332

    Article  PubMed  CAS  Google Scholar 

  12. Kalant D, Maclaren R, Cui W et al (2005) C5L2 is a functional receptor for acylation stimulatory protein. J Biol Chem 280:23936–23944

    Article  PubMed  CAS  Google Scholar 

  13. Motevalli M, Goldschmidt-Clermont PJ, Virgil D, Kwiterovich Jr PO (1997) Abnormal protein tyrosine phosphorylation in fibroblasts from hyperapoB subjects. J Biol Chem 272:24703–24709

    Article  PubMed  CAS  Google Scholar 

  14. Aouizerat BE, Allayee H, Bodnar J et al (1999) Novel genes for familial combined hyperlipidemia. Curr Opin Lipidol 10:113–122

    Article  PubMed  CAS  Google Scholar 

  15. Lusis AJ, Fogelman AM, Fonarow GC (2004) Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation 110:1868–1873

    Article  PubMed  Google Scholar 

  16. Pajukanta P, Lilja HE, Sinsheimer JS et al (2004) Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36:371–376

    Article  PubMed  CAS  Google Scholar 

  17. Allayee H, Krass KL, Pajukanta P et al. (2002) Locus for elevated apolipoprotein B levels on chromosome 1p31 in families with familial combined hyperlipidemia. Circ Res 90:926–931

    Article  PubMed  CAS  Google Scholar 

  18. Wolman M (1995) Wolman disease and its treatment. Clin Pediatr 34:207–212

    CAS  Google Scholar 

  19. Beaudet AL, Ferry GD, Nichols BL, Rosenberg HS (1977) Cholesterol ester storage disease: clinical, biochemical, and pathological studies. J Pediatr 90:910–914

    Article  PubMed  CAS  Google Scholar 

  20. Ginsberg HN, Le NA, Short MP et al (1987) Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest 80:1692–1697

    PubMed  CAS  Google Scholar 

  21. Rader DJ, Cohen J, Hobbs HH (2003) Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 111:1795–1803

    Article  PubMed  CAS  Google Scholar 

  22. Grossman M, Rader DJ, Muller DW et al (1995) A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia. Nat Med 1:1148–1154

    Article  PubMed  CAS  Google Scholar 

  23. Salen G, von Bergmann K, Lutjohann D et al and the Multicenter Sitosterolemia Study Group (2004) Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109:766–771

    Article  CAS  Google Scholar 

  24. Mahley RW, Huang Y, Rall SC Jr (1999) Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). J Lipid Res 40:1933–1949

    PubMed  CAS  Google Scholar 

  25. Hegele RA, Little JA, Vezina C (1993) Hepatic lipase deficiency: Clinical biochemical and molecular genetic characteristics. Arterioscler Thromb 13:720–728

    PubMed  CAS  Google Scholar 

  26. Brand K, Dugi KA, Brunzell JD (1996) A novel A→G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency. J Lipid Res 37:1213–1223

    PubMed  CAS  Google Scholar 

  27. Rader DJ, Brewer HB (1993) Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA 270:865–869

    Article  PubMed  CAS  Google Scholar 

  28. Wetterau JR, Aggerbeck LP, Bouma ME et al (1992) Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258:999–1001

    Article  PubMed  CAS  Google Scholar 

  29. Gabelli C, Bilato C, Martini S et al (1996) Homozygous familial hypobetalipoproteinemia. Increased LDL catabolism in hypobetalipoproteinemia due to a truncated apolipoprotein B species, apoB-87Padova. Arterioscler Thromb Biol 16:1189–1196

    CAS  Google Scholar 

  30. Breslow JL (2000) Genetics of lipoprotein abnormalities associated with coronary artery disease susceptibility. Annu Rev Genet 34:233–254

    Article  PubMed  CAS  Google Scholar 

  31. Cohen JC, Kiss RS, Pertsemlidis A et al (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305:869–872

    Article  PubMed  CAS  Google Scholar 

  32. Bruce C, Chouinard RA Jr, Tall AR (1998) Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 18:297–330

    Article  PubMed  CAS  Google Scholar 

  33. von Eckardstein A, Assmann G (1998) High density lipoproteins and reverse cholesterol transport: Lessons from mutations. Atherosclerosis 137:S7–11

    Article  Google Scholar 

  34. Nissen SE, Tsunoda T, Tuzcu EM et al (2003) Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 290:2292–2300

    Article  PubMed  CAS  Google Scholar 

  35. Brewer HB, Remaley AT, Neufeld EB et al (2004) Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 24:1755–1760

    Article  PubMed  CAS  Google Scholar 

  36. Remaley AT, Schumacher UK, Stonik JA et al (1997) Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler Thromb Biol 17:1813–1821

    CAS  Google Scholar 

  37. Calabresi L, Pisciotta L, Costantin A (2005) The molecular basis of lecithin: cholesterol acyltransferase deficiency syndromes. A comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol 25:1972–1978

    Article  PubMed  CAS  Google Scholar 

  38. Zhong S, Sharp DS, Grove JS et al (1996) Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97:2917–2923

    Article  PubMed  CAS  Google Scholar 

  39. Ikewaki K, Nishiwaki M, Sakamoto T et al (1995) Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest 96:1573–1581

    PubMed  CAS  Google Scholar 

  40. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF et al (2002) Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105:2159–2165

    Article  PubMed  CAS  Google Scholar 

  41. Clark RW, Sutfin TA, Ruggeri RB et al (2004) Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24:490–497

    Article  PubMed  CAS  Google Scholar 

  42. Brousseau ME, Schaefer EJ, Wolfe ML et al (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350:1505–1515

    Article  PubMed  CAS  Google Scholar 

  43. Marcovina SM, Koschinsky ML et al (2003) Report of the National Heart, Lung and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: Recent Advances and Future Directions. Clin Chem 49:1785–1786

    Article  PubMed  CAS  Google Scholar 

  44. NCEP: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001) JAMA 285:2486–2497

    Google Scholar 

  45. Grundy SM, Cleeman JI, Merz CN et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program. Adult Treatment Panel III guidelines. Circulation 110:227–239

    Article  PubMed  Google Scholar 

  46. Brown BG, Zhao XO, Chait A et al (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583–1592

    Article  PubMed  CAS  Google Scholar 

  47. Cannon CP, Braunwald E, McCabe CH et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504

    Article  PubMed  CAS  Google Scholar 

  48. Nissen SE, Tuzcu EM, Schoenhagen P et al (2004) Effect of intensive compared with moderate lipid lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071–1080

    Article  PubMed  CAS  Google Scholar 

  49. Ridker PM, Cannon CP, Morrow D et al (2005) C-reactive protein levels and outcomes after therapy. N Engl J Med 352:20–28

    Article  PubMed  CAS  Google Scholar 

  50. Nissen SE, Tuzcu EM, Schoenhagen P et al (2005) Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease. N Engl J Med 352:29–38

    Article  PubMed  CAS  Google Scholar 

  51. Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR (2003) Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 25:457–481

    Article  PubMed  CAS  Google Scholar 

  52. Gaist D, Rodriguez LA, Huerta C et al (2001) Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12:565–569

    Article  PubMed  CAS  Google Scholar 

  53. Altmann SW, Davis HR Jr, Zhu LJ et al (2004) Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201–1204

    Article  PubMed  CAS  Google Scholar 

  54. Fruchart J-C, Brewer HB Jr, Leitersdorf E (1998) Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 101:10S–16S

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD, 21224, USA

    Annabelle Rodriguez-Oquendo

  2. Lipid Research-Atherosclerosis Division, Department of Pediatrics, The Johns Hopkins Hospital, 550 North Broadway, Suite 312, Baltimore, MD, 21205, USA

    Peter O. Kwiterovich Jr.

Authors
  1. Annabelle Rodriguez-Oquendo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter O. Kwiterovich Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, University Hospital Groningen, Burgemeester Weertslaan 31, 8162 DP, Epe, The Netherlands

    John Fernandes

  2. Unité de Métabolisme, Département de Pédiatrie, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75043, Paris Cedex 15, France

    Jean-Marie Saudubray

  3. Metabolic Research Group, Christian de Duve Institute of Cellular Pathology, University of Louvain Medical School, Avenue Hippocrate 75-39, 1200, Brussels, Belgium

    Georges van den Berghe

  4. Willink Biochemical Genetics Unit, Royal Manchester Children’s Hospital, Hospital Road, Pendlebury, Manchester, M27 4HA, UK

    John H. Walter

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Rodriguez-Oquendo, A., Kwiterovich, P.O. (2006). Dyslipidemias. In: Fernandes, J., Saudubray, JM., van den Berghe, G., Walter, J.H. (eds) Inborn Metabolic Diseases. Springer, Berlin, Heidelberg . https://doi.org/10.1007/978-3-540-28785-8_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28785-8_32

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28783-4

  • Online ISBN: 978-3-540-28785-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation